The drug, known as suzetrigine, is the first new painkiller approved in the U.S. since 1998. It can be used to relieve pain after surgery or injury, and some researchers say it might be the start of a ...
Recent research indicates that colon cancer patients with circulating tumor DNA post-surgery may improve their survival likelihood with daily celecoxib use. Celecoxib, a COX-2 inhibitor, significantly ...
Patients with colon cancer who still have cancer cells in their blood after surgery may improve their survival odds with ...
14h
Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...
The U.S. Food and Drug Administration (FDA) on Thursday approved Journavx, the first new class of pain medication in more ...
The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than two decades. The drug, suzetrigine, is a 50-milligram prescription pill ...
A recent analysis from a randomized clinical trial conducted by researchers at the Dana-Farber Brigham Cancer Center ...
A study finds that celecoxib improves disease-free survival in stage 3 colon cancer patients with positive ctDNA after ...
In addition to ZTlido, Scilex's portfolio features Elyxyb, an oral celecoxib solution for migraines, which may also find broader use for acute pain such as tension headaches. Another product ...
Although ctDNA positivity generally meant worse disease-free survival in stage 3 resected colon cancer, patients with ctDNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback